Video reveals cancer cells' Achilles' heel (w/ Video)

Video reveals cancer cells' Achilles' heel
This image shows cancerous B cells that have been treated with rituximab. The protein CD20 (shown in green) has been drawn to the side of the cells. When the Natural Killer white blood cells approach they will stand an 80 percent chance of killing the cell if they latch on to the side where the protein has collected. Credit: MCCIR

(Medical Xpress)—Scientists from the Manchester Collaborative Centre for Inflammation Research (MCCIR) have discovered why a particular cancer drug is so effective at killing cells. Their findings could be used to aid the design of future cancer treatments.

Professor Daniel Davis and his team used high quality video imaging to investigate why the drug rituximab is so effective at killing cancerous . It is widely used in the treatment of B cell malignancies, such as lymphoma and leukaemia - as well as in like rheumatoid arthritis.

Using high-powered laser-based microscopes, researchers made videos of the process by which rituximab binds to a diseased cell and then attracts known as natural killer (NK) cells to attack. They discovered that rituximab tended to stick to one side of the cancer cell, forming a cap and drawing a number of proteins over to that side. It effectively created a front and back to the cell - with a cluster of massed on one side.

This video is not supported by your browser at this time.
B cells being killed.

But what surprised the scientists most was how this changed the effectiveness of in destroying these . When the NK cell latched onto the rituximab cap on the B cell, it had an 80% success rate at killing the cell. In contrast, when the B cell lacked this cluster of proteins on one side, it was killed only 40% of the time.

Professor Davis says: "These results were really unexpected. It was only possible for us to unravel the mystery of why this drug was so effective, through the use of video microscopy. By watching what happened within the cells we could clearly identify just why is such an effective drug – because it tended to reorganise the cancerous cell and make it especially prone to being killed."

This video is not supported by your browser at this time.
Slower version of video.

He continues: "What our findings demonstrate is that this ability to polarise a cell by moving proteins within it should be taken into consideration when new antibodies are being tested as potential treatments for . It appears that they can be up to twice as effective if they bind to a cell and reorganise it."

The findings from this study have been published online today on the website of the journal Blood. The research was carried out in collaboration with MedImmune, the global biologics research and development arm of AstraZeneca.

Commenting on the research Dr Matt Sleeman, Senior Director of Biology at MedImmune said: "Not only is this a great observation that can influence how we as a biotech company identify and design future therapies, it also shows the innovative 'out of the box' thinking that can be achieved by working in close partnership with academics at the top of their field. This unique partnership, bringing together industry and academia, demonstrates a real catalyst of scientific change within the UK, and I am excited by the potential of the MCCIR to bring further innovation that could ultimately bring benefit to patients."

More information: The paper "Rituximab causes a polarisation of B cells which augments its therapeutic function in NK cell-mediated antibody-dependent cellular cytotoxicity" has been published online on the website of the journal Blood.

Related Stories

Researchers’ blood cancer breakthrough

Aug 10, 2011

Researchers at the University of Southampton have discovered clues to why many patients do not respond to a standard drug for the blood cancer lymphoma, raising hopes that more effective treatments can be designed.

Fighting cancer with the immune system

Jun 11, 2012

The human immune system has a natural ability to identify and attack tumor cells. Natural killer (NK) cells are innate immune cells that are particularly effective at killing tumor cells due to their ability to secrete cytotoxic ...

Knocking Out Survival Protein Could Aid Leukemia Treatment

Apr 23, 2007

An effective way to fight leukemia might be to knock out a specific protein that protects cancer cells from dying, a new study shows. The findings suggest that a drug that can block this “survival protein” might on its ...

Recommended for you

Specific oxidation regulates cellular functions

30 minutes ago

For a long time, hydrogen peroxide has been considered as a dangerous metabolite that can damage cells through oxidation. This, however, is not its only role in the cell. Scientists from the German Cancer Research Center ...

New disease mechanism discovered in lymphoma

55 minutes ago

Programmed cell death is a mechanism that causes defective and potentially harmful cells to destroy themselves. It serves a number of purposes in the body, including the prevention of malignant tumor growth. ...

Researcher to cancer: 'Resistance will be futile'

8 hours ago

Turning the tables, Katherine Borden at the University of Montreal's Institute for Research in Immunology and Cancer (IRIC) has evoked Star Trek's Borg in her fight against the disease. "Cancer cells rapidly ...

How does prostate cancer form?

10 hours ago

Prostate cancer affects more than 23,000 men this year in the USA however the individual genes that initiate prostate cancer formation are poorly understood. Finding an enzyme that regulates this process ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.